Leerink Partners analyst Andrew Berens maintained a Buy rating on Mirati Therapeutics (NASDAQ:MRTX) on Friday, setting a price target of $195, which is approximately 35.42% above the present share price of $144.
Berens expects Mirati Therapeutics to post earnings per share (EPS) of -$2.08 for the second quarter of 2021.
The current consensus among 6 TipRanks analysts is for a Strong Buy rating of shares in Mirati Therapeutics, with an average price target of $249.83.
The analysts price targets range from a high of $300 to a low of $195.
In its latest earnings report, released on 12/31/2020, the company reported a quarterly revenue of $1.71 million and a net profit of -$106.34 million. The company's market cap is $7.39 billion.
According to TipRanks.com, Leerink Partners analyst Andrew Berens is currently ranked with 4 stars on a 0-5 stars ranking scale, with an average return of 8.0% and a 57.86% success rate.
Mirati Therapeutics, Inc. is a clinical-stage oncology company. The firm engages in developing a pipeline of oncology products to treat genetic, immunological and epigenetic drivers of cancer in subsets of cancer patients. Its clinical pipeline consists of glesatinib, sitravatinib and mocetinostat. The company was founded on December 13, 1995 and is headquartered in San Diego, CA.